Second Genome Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Demonstrating that a Novel Peptide, SG-3-0020, Upregulates Co-stimulatory and Checkpoint Pathways
October 7, 2021, BRISBANE, Calif.
Second Genome Announces Research Collaboration with Virginia Commonwealth University to Identify a Non-Invasive NASH Composite Biomarker
September 23, 2021, BRISBANE, Calif.
Second Genome Presents Preclinical Data at ESMO 2021 Demonstrating that a Novel Microbiome-Derived Peptide, SG-3-00802, Reverses Resistance to Anti-Programmed Death Protein-1 (PD-1) Therapy
September 16, 2021, BRISBANE, Calif.
Second Genome Announces Milestone Accomplished in Collaboration with Bayer, Demonstrating Broad Application of Company’s Machine Learning Platform to Identify Novel Proteins for the Development of Next-Generation Insect-Control Solutions
August 23, 2021, BRISBANE, Calif.
Second Genome Presents Preclinical Data Demonstrating the Effects of Microbial-Derived Metabolites in Autism Spectrum Disorder
August 10, 2021, BRISBANE, Calif.
Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers
August 5, 2021, BRISBANE, Calif.
Second Genome Presents Data at the World Microbe Forum Demonstrating Application of its Computational Platform sg-4-sight to Identify Peptides that Have the Potential to Modulate T Cell Activity in Inflammatory Bowel Disease (IBD)
June 22, 2021, BRISBANE, Calif
Second Genome to Present Big Data Analytics Capabilities at the Microbiome Data Congress
June 9, 2021, Brisbane, Calif
